Helix Biopharma Corp. (TSE:HBP) has released an update.
Helix BioPharma Corp., a clinical-stage biopharmaceutical company, has updated stakeholders on the delayed filing of its interim financial statements initially announced on March 1, 2024. While under a management cease trade order, the company successfully completed a private placement offering, raising CAD$1.915 million. They continue to work towards meeting regulatory requirements and have no further material changes or insolvency proceedings to report.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
